MMP3 and rheumatoid arthritis: In clinical trials of sinomenine (SIN) combined with MTX in the treatment of RA, there is evidence that the corresponding disease activity indicators are reduced while MMP-3 is reduced, and the corresponding imaging studies are also improved,[10] which may mean that we can intervene in the process of bone injury in RA patients by regulating MMP-3 levels.